Cargando…
Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying disea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591237/ https://www.ncbi.nlm.nih.gov/pubmed/34790672 http://dx.doi.org/10.3389/fmed.2021.728089 |
_version_ | 1784599182687862784 |
---|---|
author | Li, Ning Lv, Dan Zhu, Xiangjun Wei, Ping Gui, Yuan Liu, Shijia Zhou, Enchao Zheng, Min Zhou, Dong Zhang, Lu |
author_facet | Li, Ning Lv, Dan Zhu, Xiangjun Wei, Ping Gui, Yuan Liu, Shijia Zhou, Enchao Zheng, Min Zhou, Dong Zhang, Lu |
author_sort | Li, Ning |
collection | PubMed |
description | Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying diseases remains unclear. Method: We systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021 to identify eligible trials. The primary outcome was a composite of worsening kidney function, end-stage kidney disease (ESKD), or renal death. Efficacy and safety outcomes were stratified by baseline features, such as type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, proteinuria, and renal function. Results: A total of nine studies were included. These studies included 25,749 patients with estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m(2) and 12,863 patients with urine albumin-to-creatinine ratio (UACR) >300 mg/g. SGLT2 inhibitors reduced the risk of the primary renal outcome by 30% in patients with eGFR<60 mL/min/1.73 m(2) (HR 0.70, [95% CI 0.58–0.83], I(2) = 0.00%) and by 43% in patients with UACR > 300 mg/g (HR 0.57, [95% CI 0.48–0.67], I(2) = 16.59%). A similar benefit was observed in CKD patients with type 2 diabetes. SGLT2 inhibitors had no clear effects on renal outcomes in patients with eGFR<60 mL/min/1.73 m(2) combined with atherosclerotic cardiovascular disease (HR 0.74, [95% CI 0.51–1.06], I(2) = 0.00%). However, they reduced the risk of major renal outcomes by 46% (HR 0.54, [95% CI 0.38–0.76], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease and macroalbuminuria (defined as UACR > 300 mg/g). SGLT2 inhibitors did not significantly reduce the risk of major renal outcomes in CKD patients with heart failure (eGFR<60 mL/min/1.73 m(2): HR 0.81, [95% CI 0.47–1.38], I(2) = 0.00%; UACR > 300 mg/g: HR 0.66, [95% CI 0.41–1.07], I(2) = 0.00%). SGLT2 inhibitors showed consistent renal benefits across different levels of eGFR (P interaction = 0.48). Conclusion: SGLT2 inhibitors significantly reduced the risk of the primary outcome in CKD patients. However, for patients with different features and underlying diseases, there exists differences in the renal protective effect. |
format | Online Article Text |
id | pubmed-8591237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85912372021-11-16 Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis Li, Ning Lv, Dan Zhu, Xiangjun Wei, Ping Gui, Yuan Liu, Shijia Zhou, Enchao Zheng, Min Zhou, Dong Zhang, Lu Front Med (Lausanne) Medicine Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in recent trials. However, the magnitude of renal benefits for CKD patients with different baseline features and underlying diseases remains unclear. Method: We systematically searched the Embase, PubMed, Web of Science, and Cochrane library databases from inception to April 15, 2021 to identify eligible trials. The primary outcome was a composite of worsening kidney function, end-stage kidney disease (ESKD), or renal death. Efficacy and safety outcomes were stratified by baseline features, such as type 2 diabetes, heart failure, atherosclerotic cardiovascular disease, proteinuria, and renal function. Results: A total of nine studies were included. These studies included 25,749 patients with estimated glomerular filtration rate (eGFR)<60 mL/min/1.73 m(2) and 12,863 patients with urine albumin-to-creatinine ratio (UACR) >300 mg/g. SGLT2 inhibitors reduced the risk of the primary renal outcome by 30% in patients with eGFR<60 mL/min/1.73 m(2) (HR 0.70, [95% CI 0.58–0.83], I(2) = 0.00%) and by 43% in patients with UACR > 300 mg/g (HR 0.57, [95% CI 0.48–0.67], I(2) = 16.59%). A similar benefit was observed in CKD patients with type 2 diabetes. SGLT2 inhibitors had no clear effects on renal outcomes in patients with eGFR<60 mL/min/1.73 m(2) combined with atherosclerotic cardiovascular disease (HR 0.74, [95% CI 0.51–1.06], I(2) = 0.00%). However, they reduced the risk of major renal outcomes by 46% (HR 0.54, [95% CI 0.38–0.76], I(2) = 0.00%) in patients with atherosclerotic cardiovascular disease and macroalbuminuria (defined as UACR > 300 mg/g). SGLT2 inhibitors did not significantly reduce the risk of major renal outcomes in CKD patients with heart failure (eGFR<60 mL/min/1.73 m(2): HR 0.81, [95% CI 0.47–1.38], I(2) = 0.00%; UACR > 300 mg/g: HR 0.66, [95% CI 0.41–1.07], I(2) = 0.00%). SGLT2 inhibitors showed consistent renal benefits across different levels of eGFR (P interaction = 0.48). Conclusion: SGLT2 inhibitors significantly reduced the risk of the primary outcome in CKD patients. However, for patients with different features and underlying diseases, there exists differences in the renal protective effect. Frontiers Media S.A. 2021-11-01 /pmc/articles/PMC8591237/ /pubmed/34790672 http://dx.doi.org/10.3389/fmed.2021.728089 Text en Copyright © 2021 Li, Lv, Zhu, Wei, Gui, Liu, Zhou, Zheng, Zhou and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Li, Ning Lv, Dan Zhu, Xiangjun Wei, Ping Gui, Yuan Liu, Shijia Zhou, Enchao Zheng, Min Zhou, Dong Zhang, Lu Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title | Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title_full | Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title_fullStr | Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title_full_unstemmed | Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title_short | Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis |
title_sort | effects of sglt2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591237/ https://www.ncbi.nlm.nih.gov/pubmed/34790672 http://dx.doi.org/10.3389/fmed.2021.728089 |
work_keys_str_mv | AT lining effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT lvdan effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT zhuxiangjun effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT weiping effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT guiyuan effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT liushijia effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT zhouenchao effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT zhengmin effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT zhoudong effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis AT zhanglu effectsofsglt2inhibitorsonrenaloutcomesinpatientswithchronickidneydiseaseametaanalysis |